Unitree's R1 brings smart humanoid robots within reach
Even more remarkable is its price: $5,900.
China-based Unitree has designed the R1 as an affordable, lightweight humanoid robot and is aiming it at developers, tech enthusiasts, research labs, and educational institutions, though actually anyone can buy it.
It's not clear if Unitree has any particular ambitions for the practical use of the R1, but that's partly why it's making it available to one and all, as developers will no doubt be keen to see what they can get it doing. A home help? Perhaps. Face-to-robot-face customer service at malls, airports, and hotels? Maybe. Entertainers? That already looks like a safe bet.
The R1 humanoid robot stands at 47.6 inches (1.21 meters) tall and tips the scales at 55 pounds (25 kg).
As you can see from the footage in the video at the top of this page, the robot is extremely versatile, thanks in part to its 26 functional joints, which, to be frank, is more than what many humans have the day after some particularly strenuous exercise.
The R1 is powered by a lithium battery, but at the current time it can only offer one hour of operation before it needs charging. Sadly, unlike Ubtech's Walker S2 robot, it can't swap out its own batteries, so you'll have to do that yourself.
Importantly, it also comes with a remote control, so you can quickly turn it off in the unlikely event that it suddenly goes rogue.
Notably, the R1 costs considerably less than Unitree's more complex G1, another humanoid robot that it released last year for $16,000.
Compared to the G1, the R1 has been deliberately designed to be a simpler humanoid robot suitable for educational and light research use.
Unitree is one of a growing number of tech firms globally that are developing smart, agile, bipedal robots. The technology has improved dramatically in recent years, with many companies eyeing them for industrial use where they can work alongside human workers, though of course many suggest that at some point those human workers will be replaced.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Buy, Sell or Hold Navitas Stock? Key Tips Ahead of Q2 Earnings
Navitas Semiconductor NVTS is set to release its second-quarter 2025 results on Aug. the second quarter of 2025, net revenues are expected to be between $18 and $20 million. The Zacks Consensus Estimate for second-quarter revenues is pegged at $14.5 million, suggesting a year-over-year decline of 29.1%. The consensus mark for loss is pegged at 5 cents per share for the second quarter of 2025, unchanged over the past 30 days. NVTS reported a loss of 7 cents per share in the year-ago quarter. Navitas Semiconductor Corporation Price and EPS Surprise Navitas Semiconductor Corporation price-eps-surprise | Navitas Semiconductor Corporation Quote Let's see how things have shaped up for this announcement. Key Factors to Note for NVTS Earnings Navitas Semiconductor is a well-known provider of power semiconductors driven by its GaN (gallium nitride) business, under GaNFast, GaNSafe and GaNSense brands. Investments by NVIDIA NVDA and Tesla in GaN technology, as well as expanding footprint across mobile, electric vehicle (EV), and energy sectors, bode well for Navitas' prospects. However, sluggishness in solar, EV and industrial end-markets is expected to have negatively impacted second-quarter 2025 results. Unfavorable product mix is expected to have hurt gross margin in the to-be-reported quarter. Uncertainty over tariffs and trade issues between the United States and China has been a headwind for Navitas. NVTS Shares Outperform Sector Navitas Semiconductor shares have jumped 97.8% year to date, outperforming the broader Zacks Computer and Technology sector's return of 11.4% and the Zacks Electronics Semiconductors industry's return of 16.7%. NVTS Stock's Performance Image Source: Zacks Investment Research Navitas Semiconductor stock is not so cheap, as the Value Score of F suggests a stretched valuation at this terms of the forward 12-month Price/Sales, NVTS is trading at 16.92X, higher than the broader sector's 6.71X. Price/Sales (F12M) Image Source: Zacks Investment Research Navitas Semiconductor stock is currently trading above the 50-day and 200-day moving averages, indicating a bullish trend. NVTS Stock Trades Above 50-Day and 200-Day SMAs Image Source: Zacks Investment Research NVTS' Strong Portfolio Aids Growth Amid Stiff Competition Navitas Semiconductor is ramping up new 80 - 120V GaN devices in 2025 to target the 48V DC-DC converter market. In Solar & Energy Storage, the launch of NVTS' bidirectional GaN ICs – GaN BDS, in the first quarter of 2025, is enabling single-stage power conversion. This disrupts traditional two-stage architectures used in more than 70% of power electronics, reducing cost, size and power loss by 30% or more. The innovation reveals high-efficiency applications across solar microinverters, EV onboard chargers, energy storage and motor control systems, with customer ramp-ups expected in late 2025 and the EV domain, NVTS has secured more than 40 design wins across China, Europe, the United States and Korea. With a rapidly expanding $900 million EV pipeline, Navitas is poised to scale in high-voltage, high-efficiency onboard and roadside chargers beginning in expanding relationship with NVIDIA is noteworthy. In May, Navitas Semiconductor collaborated with NVIDIA to support the development of NVIDIA's new 800V high-voltage DC (HVDC) architecture. NVIDIA's 800V HVDC approach is designed for next-generation AI data centers, including systems like NVIDIA Rubin Ultra. NVIDIA 800V HVDC architecture will improve end-to-end power efficiency up to 5%, reduce maintenance costs by 70%, and lower cooling costs, all using NVTS' GaNFast and GeneSiC power Navitas Semiconductor faces significant competition from the likes of Wolfspeed WOLF and Power Integrations POWI. These rivals continue to invest aggressively in wide bandgap technologies, supported by stronger revenue bases and deeper customer relationships. Power Integrations' GaN portfolio includes InnoSwitch3, InnoMux-2 ICs, HiperPFS and Scale-2 Gate Drivers. Power Integrations is the only GaN supplier offering devices rated at 900V, 1250V and 1700V, giving it an advantage in grid-tolerant and high-voltage applications. Wolfspeed has been taking initiatives to expand manufacturing capacity. A state-of-the-art, automated 200-millimeter (mm) capable silicon carbide device fabrication facility in New York (the Mohawk Valley fab) is noteworthy. Wolfspeed enjoys a first-mover advantage in 200-mm wafer volume production, which is the silicon carbide industry's most advanced technology. Conclusion NVTS' muted revenue growth outlook in the near term, along with a stretched valuation, makes the stock risky for investors. Navitas Semiconductor currently has a Zacks Rank #4 (Sell), which implies that investors should avoid the stock ahead of second-quarter 2025 results. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Power Integrations, Inc. (POWI) : Free Stock Analysis Report Wolfspeed (WOLF) : Free Stock Analysis Report Navitas Semiconductor Corporation (NVTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
an hour ago
- Entrepreneur
Cash Rush: Top Startup Funding Highlights (July 26–Aug 1)
From AI innovations to fintech powerhouses, these startups secured big investor bets this week. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. The startup ecosystem saw a vibrant week of funding activity, with a mix of AI-driven innovations, fintech disruptors, and specialised platforms securing capital to fuel their next growth phase. From cybersecurity and semiconductor intelligence to edtech and gaming communities, these ventures are redefining industries with technology-first approaches and strong investor backing. Here's a snapshot of the week's biggest deals. SAFE – Cybersecurity Risk Quantification SAFE offers cybersecurity risk quantification and management services, enabling organisations to measure, prioritise, and mitigate cyber threats across digital infrastructure. Formerly known as Lucideus, Safe Security safeguards Fortune 500 companies with continuous risk assessments and actionable insights. Inception: 2012 2012 Founder: Saket Modi Saket Modi Based-out: California California Funding Amount: USD 70 Million USD 70 Million Investors: Avataar Ventures, Susquehanna Asia Venture Capital, NextEquity Partners, Prosperity7 Ventures, Eight Roads, John Chambers, Sorenson Capital Navi Technologies – Tech-Led Financial Services Navi operates a digital-first financial services platform offering personal and home loans via its NBFC arm, Navi Finserv. Its offerings extend to mutual funds, health insurance, and UPI-based payment solutions, making it a comprehensive financial ecosystem for retail consumers. Inception: 2018 2018 Founders: Sachin Bansal, Ankit Agarwal Sachin Bansal, Ankit Agarwal Based-out: Bengaluru Bengaluru Funding Amount: USD 20 Million USD 20 Million Investors: PhillipCapital, NDX Finserve, Aarpee Group, Ambit Finvest, and others Metaforms – AI Agents for Market Research Metaforms develops AI-driven agents that streamline market research workflows. From automating survey programming to data processing and vendor coordination, the platform enables faster turnarounds and scalability for research agencies. Inception: 2022 2022 Founders: Akshat Tyagi, Arjun S Akshat Tyagi, Arjun S Based-out: Bengaluru Bengaluru Funding Amount: USD 9 Million USD 9 Million Investors: Peak XV Partners, Nexus Venture Partners, Together Fund STAN – Social Platform for Gaming Creators STAN is a mobile-first platform empowering gaming creators, publishers, and communities through live audio, creator clubs, monetisation tools, and brand-led campaigns. It facilitates community building and engagement in gaming culture. Inception: 2022 2022 Founders: Parth Chadha, Rahul Singh, Nauman Mulla Parth Chadha, Rahul Singh, Nauman Mulla Based-out: Bengaluru Bengaluru Funding Amount: USD 8.5 Million USD 8.5 Million Investors: Google's AI Futures Fund, Bandai Namco Entertainment, Square Enix, Reazon Holdings, Aptos Labs, General Catalyst, GFR Fund, T-Accelerate Capital, Pix Capital SixSense – AI for Semiconductor Manufacturing SixSense uses AI to analyse semiconductor production data, detect critical defects, and predict process deviations. Its platform boosts throughput, reduces waste, and shifts manufacturing from reactive inspection to proactive control. Inception: 2018 2018 Founders: Akanksha Jagwani, Avni Agarwal Akanksha Jagwani, Avni Agarwal Based-out: Singapore Singapore Funding Amount: USD 8.5 Million USD 8.5 Million Investors: Peak XV's Surge, Alpha Intelligence Capital, Febe, and others Arivihan – AI-Powered Rural Learning Arivihan delivers personalised, AI-driven learning to students in smaller towns and rural areas. Its platform includes interactive lectures, instant doubt-solving, and tailored study plans for board and NEET exam preparation. Inception: 2024 2024 Founders: Ritesh Singh Chandel, Sonu Kumar, Rushabh Kothari Ritesh Singh Chandel, Sonu Kumar, Rushabh Kothari Based-out: Bengaluru Bengaluru Funding Amount: USD 4.17 Million USD 4.17 Million Investors: Prosus, Accel, GSF Investors – AI for Sales Performance provides a SaaS platform that boosts frontline sales productivity with personalised pitches, contextual coaching, and dynamic content. It serves major enterprises across BFSI, healthcare, consumer goods, and more. Inception: 2022 2022 Founders: Hanuman Kamma, Arun Subramanian Hanuman Kamma, Arun Subramanian Based-out: Mumbai Mumbai Funding Amount: USD 3.47 Million USD 3.47 Million Investors: Equentis Angel Fund These startups highlight how innovation and strategic funding continue to drive transformative solutions across industries.
